Delcath Systems Resultados de beneficios anteriores
Pasado controles de criterios 3/6
Delcath Systems ha aumentado sus beneficios a una tasa media anual de 17.2%, mientras que los beneficios de la industria de Medical Equipment han experimentado un crecimiento de 13.6% anual. Los ingresos han ido creciendo a una tasa media de 73.6% al año. La rentabilidad financiera de Delcath Systems es de 0.5%, y sus márgenes netos son de 0.6%.
Información clave
17.20%
Tasa de crecimiento de los beneficios
41.27%
Tasa de crecimiento del BPA
| Crecimiento de la industria Medical Equipment | 8.90% |
| Tasa de crecimiento de los ingresos | 73.57% |
| Rentabilidad financiera | 0.50% |
| Margen neto | 0.62% |
| Última actualización de beneficios | 31 Mar 2026 |
Actualizaciones de resultados anteriores recientes
Recent updates
Actualización de narrativa • Apr 30
DCTH: 2026 Spend Increase Will Drive Hepatic Cancer Therapy Adoption
Analysts have trimmed their blended price target on Delcath Systems by about $2 to align with recent Street research that lowered the target to $27, citing updated FY26 sales guidance of at least $100m and sharply higher planned R&D and SG&A spending to support HEPZATO commercial and label expansion efforts. Analyst Commentary Bullish Takeaways Bullish analysts view the revised US$27 price target as still reflecting upside potential relative to current trading levels, even after trimming expectations.Actualización de narrativa • Apr 16
DCTH: 2026 Spend Increase Will Support Hepatic Cancer Therapy Expansion
Analysts trimmed their price target on Delcath Systems to $27 from $29, citing updated guidance for at least $100M in FY26 sales and a very large projected increase in R&D and SG&A spending to support the HEPZATO label and commercial expansion. Analyst Commentary Recent commentary focuses on how the updated FY26 sales outlook and higher operating spend could affect the risk and reward profile for Delcath Systems, especially around execution on HEPZATO and future label opportunities.
Actualización de narrativa • Apr 02
DCTH: Higher 2026 Spending Will Support Liver Cancer Therapy Expansion
Analysts have trimmed their average price target on Delcath Systems by $2, citing recent FY25 results, updated FY26 sales guidance of at least $100M versus prior consensus of $111M, and expectations for higher R&D and SG&A spending to support HEPZATO growth and label expansion. Analyst Commentary Recent Street commentary on Delcath Systems centers on how near term spending and updated sales guidance could affect the risk and reward profile for shareholders.Actualización de narrativa • Mar 18
DCTH: Higher 2026 Spending Will Support Cancer Therapy Cash Flows And Expansion
Narrative Update on Delcath Systems The analyst price target for Delcath Systems has been trimmed by $2 to $27, as analysts factor in the company's FY26 sales guidance of at least $100M, along with sharply higher planned R&D and SG&A spending to support HEPZATO and label expansion. Analyst Commentary Recent research updates on Delcath Systems highlight a mixed reaction to the company’s outlook, with particular attention on FY26 guidance and the spending required to support HEPZATO and label expansion.Actualización de narrativa • Mar 04
DCTH: Higher 2026 Spending Will Support Future Revenue Expansion Potential
Narrative Update on Delcath Systems The analyst price target for Delcath Systems has been reduced by $3 to $27. Analysts point to updated FY26 sales guidance of at least $100M and significantly higher projected R&D and SG&A spending to support HEPZATO growth and label expansion as key factors behind the change.Actualización de narrativa • Feb 18
DCTH: Steadier Cancer Therapy Cash Flows Will Support Future Indication Expansion
Analysts have raised their price target on Delcath Systems by $1 to $29, citing preliminary Q4 results that indicate Hepzato is becoming a more stable revenue contributor, with more predictable quarter-to-quarter trends and cash flow that may support expansion plans. Analyst Commentary Analysts highlighting the new US$29 price target point to Hepzato’s role as a steadier revenue source and to cash flow that may help support future expansion plans.Actualización de narrativa • Feb 04
DCTH: Steadier Liver Cancer Therapy Revenues Will Support Future Indication Expansion
Analysts have nudged their price target on Delcath Systems higher to $29 from $28, pointing to Hepzato's role as a steady revenue contributor with more predictable quarter to quarter variability and cash flow that can support expansion of additional indications. Analyst Commentary Even with the higher price target, not all commentary around Delcath Systems leans positive.Actualización de narrativa • Jan 20
DCTH: Steadier Hepatic Therapy Uptake Will Support Future Expansion Plans
Analysts recently lifted their price target on Delcath Systems to $29 from $28, citing Hepzato's role as a steadier and more predictable contributor to revenue and cash flow. They believe this supports potential expansion plans and informs modest adjustments to growth, margin, and future P/E assumptions.Actualización de narrativa • Jan 06
DCTH: CHOPIN Trial Data Will Support Future Uptake Despite Softer Guidance
Analysts have kept their fair value estimate for Delcath Systems steady at $18.00 while adjusting underlying assumptions, citing mixed reactions to softer Q3 and FY2025 revenue guidance alongside supportive CHOPIN trial data and a range of updated price targets from $20 to $30. Analyst Commentary Street research on Delcath Systems has centered on the tension between supportive CHOPIN trial data and softer near term revenue guidance, with several price target revisions reflecting this mixed setup.Actualización de narrativa • Dec 14
DCTH: CHOPIN Data Expected To Drive Stronger Uptake Despite Near-Term Guidance Reset
Analysts have trimmed their fair value estimate for Delcath Systems to $18.00 from $21.00, reflecting lower near term revenue growth assumptions after soft preliminary guidance. This comes despite sustained confidence in Hepzato uptake driven by positive CHOPIN trial data and improving profit margin expectations.Artículo de análisis • Nov 21
Why We're Not Concerned Yet About Delcath Systems, Inc.'s (NASDAQ:DCTH) 28% Share Price Plunge
The Delcath Systems, Inc. ( NASDAQ:DCTH ) share price has fared very poorly over the last month, falling by a...Seeking Alpha • Nov 06
Delcath: Temporary Headwinds Are No Cause For Concern
Summary Delcath's third quarter was weak due to seasonality and pricing headwinds, but data suggests these are temporary challenges. Delcath continues to expand its treatment sites and sales force, which should lead to strong growth in 2026. Clinical trials to expand the company's addressable market are also now under way, which could provide enormous upside in several years time. Delcath's valuation is extremely low given the prospect of continued growth and strong margins once growth investments normalize. Read the full article on Seeking AlphaArtículo de análisis • Oct 28
The Delcath Systems, Inc. (NASDAQ:DCTH) Analysts Have Been Trimming Their Sales Forecasts
The latest analyst coverage could presage a bad day for Delcath Systems, Inc. ( NASDAQ:DCTH ), with the analysts making...Artículo de análisis • Aug 09
Delcath Systems, Inc. Just Recorded A 200% EPS Beat: Here's What Analysts Are Forecasting Next
NasdaqCM:DCTH 1 Year Share Price vs Fair Value Explore Delcath Systems's Fair Values from the Community and select...Artículo de análisis • Jul 12
Why We're Not Concerned Yet About Delcath Systems, Inc.'s (NASDAQ:DCTH) 29% Share Price Plunge
Delcath Systems, Inc. ( NASDAQ:DCTH ) shares have retraced a considerable 29% in the last month, reversing a fair...Artículo de análisis • Jun 18
Delcath Systems (NASDAQ:DCTH) Is In A Strong Position To Grow Its Business
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...Artículo de análisis • May 22
Delcath Systems, Inc.'s (NASDAQ:DCTH) 52% Jump Shows Its Popularity With Investors
Delcath Systems, Inc. ( NASDAQ:DCTH ) shareholders would be excited to see that the share price has had a great month...Artículo de análisis • May 11
Delcath Systems, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
A week ago, Delcath Systems, Inc. ( NASDAQ:DCTH ) came out with a strong set of first-quarter numbers that could...
Nueva narrativa • May 02
HEPZATO Launch And European Expansion Will Expand Treatment Access
Expansion in U.S. treatment centers and commercial teams is expected to drive significant revenue growth and improve operational efficiencies.Artículo de análisis • Mar 11
With A 27% Price Drop For Delcath Systems, Inc. (NASDAQ:DCTH) You'll Still Get What You Pay For
Delcath Systems, Inc. ( NASDAQ:DCTH ) shares have retraced a considerable 27% in the last month, reversing a fair...Artículo de análisis • Jan 18
Delcath Systems, Inc.'s (NASDAQ:DCTH) P/S Is Still On The Mark Following 31% Share Price Bounce
Delcath Systems, Inc. ( NASDAQ:DCTH ) shareholders have had their patience rewarded with a 31% share price jump in the...Artículo de análisis • Dec 19
Does Delcath Systems (NASDAQ:DCTH) Have A Healthy Balance Sheet?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...Seeking Alpha • Nov 18
Delcath Systems: Q3 Earnings Reveal HEPZATO KIT And CHEMOSAT Growth
Summary Delcath Systems' Q3 earnings revealed strong growth with $11.2M in revenue, driven by HEPZATO and CHEMOSAT sales, and an 85% gross margin. The company is expanding its commercial footprint with 12 active treatment centers and plans to reach 30 by the end of 2025. Promising growth drivers include new cancer indications for HEPZATO, potential label expansion, and combining with immune checkpoint inhibitors. Despite promising trends, investors should be cautious of seasonality impacts and the risks associated with upcoming Phase II trials and increased R&D expenses. I take a look at the charts to see if I can identify an opportunity to add to my position. Read the full article on Seeking AlphaArtículo de análisis • Nov 01
Delcath Systems, Inc.'s (NASDAQ:DCTH) P/S Is Still On The Mark Following 26% Share Price Bounce
Despite an already strong run, Delcath Systems, Inc. ( NASDAQ:DCTH ) shares have been powering on, with a gain of 26...Artículo de análisis • Sep 10
Delcath Systems, Inc.'s (NASDAQ:DCTH) 26% Jump Shows Its Popularity With Investors
Delcath Systems, Inc. ( NASDAQ:DCTH ) shares have continued their recent momentum with a 26% gain in the last month...Artículo de análisis • Aug 27
Is Delcath Systems (NASDAQ:DCTH) A Risky Investment?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Artículo de análisis • Aug 07
Delcath Systems, Inc. (NASDAQ:DCTH) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
Shareholders might have noticed that Delcath Systems, Inc. ( NASDAQ:DCTH ) filed its quarterly result this time last...Artículo de análisis • Jan 15
Is Delcath Systems (NASDAQ:DCTH) Using Debt In A Risky Way?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Desglose de ingresos y gastos
Desglose de ingresos y gastos
Cómo gana y gasta dinero Delcath Systems. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).
Historial de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Gastos G+A | Gastos de I+D |
|---|---|---|---|---|
| 31 Mar 26 | 90 | 1 | 45 | 34 |
| 31 Dec 25 | 85 | 3 | 44 | 29 |
| 30 Sep 25 | 80 | 1 | 40 | 23 |
| 30 Jun 25 | 70 | 2 | 37 | 19 |
| 31 Mar 25 | 54 | -14 | 32 | 15 |
| 31 Dec 24 | 37 | -26 | 30 | 14 |
| 30 Sep 24 | 23 | -34 | 29 | 16 |
| 30 Jun 24 | 12 | -56 | 29 | 16 |
| 31 Mar 24 | 5 | -50 | 27 | 17 |
| 31 Dec 23 | 2 | -48 | 22 | 18 |
| 30 Sep 23 | 2 | -45 | 19 | 17 |
| 30 Jun 23 | 3 | -34 | 18 | 17 |
| 31 Mar 23 | 3 | -37 | 17 | 19 |
| 31 Dec 22 | 3 | -37 | 17 | 19 |
| 30 Sep 22 | 4 | -33 | 16 | 18 |
| 30 Jun 22 | 4 | -32 | 16 | 17 |
| 31 Mar 22 | 4 | -28 | 15 | 15 |
| 31 Dec 21 | 4 | -26 | 14 | 14 |
| 30 Sep 21 | 2 | -27 | 15 | 13 |
| 30 Jun 21 | 2 | -25 | 13 | 13 |
| 31 Mar 21 | 2 | -23 | 12 | 12 |
| 31 Dec 20 | 2 | -24 | 11 | 11 |
| 30 Sep 20 | 2 | -5 | 8 | 11 |
| 30 Jun 20 | 2 | -7 | 10 | 10 |
| 31 Mar 20 | 2 | -9 | 10 | 9 |
| 31 Dec 19 | 2 | -9 | 10 | 9 |
| 30 Sep 19 | 2 | -32 | 12 | 13 |
| 30 Jun 19 | 3 | -34 | 10 | 15 |
| 31 Mar 19 | 3 | -34 | 10 | 17 |
| 31 Dec 18 | 3 | -19 | 10 | 20 |
| 30 Sep 18 | 3 | -28 | 9 | 17 |
| 30 Jun 18 | 3 | -32 | 10 | 15 |
| 31 Mar 18 | 3 | -27 | 10 | 14 |
| 31 Dec 17 | 3 | -46 | 10 | 10 |
| 30 Sep 17 | 3 | -34 | 10 | 10 |
| 30 Jun 17 | 2 | -23 | 10 | 10 |
| 31 Mar 17 | 2 | -27 | 9 | 9 |
| 31 Dec 16 | 2 | -18 | 9 | 8 |
| 30 Sep 16 | 2 | -15 | 9 | 8 |
| 30 Jun 16 | 2 | -16 | 9 | 7 |
| 31 Mar 16 | 2 | -13 | 9 | 7 |
| 31 Dec 15 | 2 | -15 | 10 | 6 |
| 30 Sep 15 | 2 | -13 | 11 | 5 |
| 30 Jun 15 | 1 | -15 | 12 | 4 |
Ingresos de calidad: DCTH tiene ganancias de alta calidad.
Margen de beneficios creciente: DCTH pasó a ser rentable.
Análisis del flujo de caja libre vs. Beneficios
Análisis del crecimiento de los beneficios en el pasado
Tendencia de beneficios: DCTH ha pasado a ser rentable en los últimos 5 años, con un crecimiento de los beneficios de 17.2% al año.
Acelerando crecimiento: DCTH ha pasado a ser rentable en el último año, lo que dificulta la comparación de la tasa de crecimiento de los beneficios con su promedio de 5 años.
Beneficios vs. Industria: DCTH ha pasado a ser rentable en el último año, lo que es difícil comparar el crecimiento de sus beneficios en el último año con el de la industria Medical Equipment (14.8%).
Rentabilidad financiera
Alta ROE: La rentabilidad financiera de DCTH (0.5%) se considera baja.
Rentabilidad económica
Rendimiento del capital invertido
Descubre empresas con buenos resultados en el pasado
Análisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/05/22 17:47 |
| Precio de las acciones al final del día | 2026/05/22 00:00 |
| Beneficios | 2026/03/31 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Delcath Systems, Inc. está cubierta por 12 analistas. 6 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Michael Gorman | BTIG |
| Marie Thibault | BTIG |
| John Newman | Canaccord Genuity |